Prosecution Insights
Last updated: April 19, 2026
Application No. 17/918,162

ANTIBACTERIAL AGENT AGAINST PERIODONTAL DISEASE-ASSOCIATED BACTERIUM AND DENTAL CARIES-ASSOCIATED BACTERIUM, COMPOSITION FOR PERIODONTAL DISEASE PROPHYLAXIS AND TREATMENT, COMPOSITION FOR CAVITY PROPHYLAXIS AND TREATMENT, COMPOSITION FOR GUM IMPROVEMENT, COMPOSITION FOR GUM RIDGE IMPROVEMENT, COMPOSITION FOR INHIBITING PLAQUE ACCUMULATION, COMPOSITION FOR XEROSTOMIA IMPROVEMENT, COMPOSITION FOR SALIVA IMPROVEMENT, COMPOSITION FOR INHIBITING BAD BREATH, AND COMPOSITION FOR CONSTIPATION IMPROVEMEN

Non-Final OA §102
Filed
Oct 11, 2022
Examiner
WEBB, WALTER E
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tokiwa Phytochemical Co., Ltd.
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
3y 0m
To Grant
66%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allow Rate
454 granted / 977 resolved
-13.5% vs TC avg
Strong +19% interview lift
Without
With
+19.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
60 currently pending
Career history
1037
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
48.3%
+8.3% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
15.4%
-24.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 977 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 5, 10, 12-14 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Delbo (CN107365629). Delbo teaches “dental care products, concretely relate to a kind of spearmint oil bay extract essense and preparation method thereof, and the preparation method that essence is applied in toothpaste” (Abstract). The prior art teaches a specific embodiment of a toothpaste composition comprising 2.20% “Spearmint oil bay extract essence” (Embodiment I at p. 14 of translation), wherein the “bay extract” is from “(Laurus nobilis) Lauraceae Laurus” (12th page of Translation at 5th paragraph). Delbo further teaches, “Laurin oil is from bay tree (Laurus Nobilis) extract, belong to Lauraceae bay” and “can be used for treating rheumatism, neuralgia, muscle Bitterly, the circulatory system is smooth, flu, influenza, various focusing depths represented, skin infection, diarrhoea, it is also beneficial for hair restoration and health-care Place, smell are sweet tea, pure and fresh, slightly pungent taste” (Id.) The prior art is anticipatory insofar as it teaches a composition comprising bay tree (Laurus nobilis L.) extract as active ingredient. Technological Background The prior art made of record and not relied upon is considered pertinent to applicant's disclosure Chauhan (Planet Ayurveda_2019). Chauhan is pertinent for teaching uses, benefits, dosages of the bay leaf (Laurus nobilis) extract (p. 2, para. [0019]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to WALTER E WEBB whose telephone number is (571)270-3287. The examiner can normally be reached Mon-Fri 7-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Frederick Krass can be reached on (571)272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /WALTER E WEBB/ Primary Examiner Art Unit 1612
Read full office action

Prosecution Timeline

Oct 11, 2022
Application Filed
Mar 21, 2025
Non-Final Rejection — §102
Sep 25, 2025
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582600
STABLE GEL COMPOSITION HAVING HIGH OIL CONTENT, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12570932
REMOVAL AND PREVENTION OF BIOFILM BY NANOPARTICLE CHEMISTRIES
2y 5m to grant Granted Mar 10, 2026
Patent 12564657
MOULDABLE ARTIFICIAL BONE COMPOSITE MATERIAL AND PREPARATION METHOD THEREOF
2y 5m to grant Granted Mar 03, 2026
Patent 12564544
THICKENED ALKALYZATION COMPONENT FOR OXIDATIVE HAIR LIGHTENING PRODUCT
2y 5m to grant Granted Mar 03, 2026
Patent 12551425
AQUEOUS ZINC ORAL CARE COMPOSITIONS WITH FLUORIDE
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
66%
With Interview (+19.0%)
3y 0m
Median Time to Grant
Low
PTA Risk
Based on 977 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month